Systemic Lupus Erythematosus
A complex autoimmune disease where the body's immune system attacks its own tissues and organs, often causing a butterfly-shaped facial rash, joint pain, and kidney damage.
Emergency Management: Lupus Cerebritis (presenting with intractable seizures, acute psychosis, or coma) or Alveolar Hemorrhage (presenting with hemoptysis and dropping hematocrit). Require ICU admission, plasmapheresis, and high-dose IV pulse steroids (Methylprednisolone 1000mg IV) plus Cyclophosphamide.
Systemic Lupus Erythematosus is a chronic, relapsing-remitting, multisystem autoimmune disease characterized by a loss of self-tolerance, leading to the production of pathogenic autoantibodies and immune complex deposition in tissues. It can affect virtually any organ, most notably the skin, joints, kidneys, and central nervous system.
Detailed Overview
SLE is the prototype of a systemic autoimmune disease. It is marked by a vast array of autoantibodies, particularly antinuclear antibodies (ANA), which target intracellular antigens. The pathophysiology involves defective clearance of apoptotic cells, triggering an abnormal immune response. Clinical manifestations range from mild mucocutaneous and joint involvement to life-threatening lupus nephritis and cerebritis. The disease runs a completely unpredictable course of flares and remissions.
Epidemiology & Demographics
Prevalence is roughly 20-150 per 100,000. Striking female predominance, particularly during reproductive years (female-to-male ratio of 9:1). Higher incidence and more severe disease observed in African American, Hispanic, and Asian populations.
Etiological Mechanism
A multifactorial interplay of genetic susceptibility (HLA-DR2, HLA-DR3, complement deficiencies like C1q, C2, C4), hormonal factors (estrogen), and environmental triggers (ultraviolet light, Epstein-Barr virus, silica dust).
Primary Causes
Loss of self-tolerance leading to autoantibody production. Environmental triggers like UV light cause keratinocyte apoptosis; defective clearance of these apoptotic cells exposes nuclear antigens to the immune system, initiating the autoimmune cascade.
Defective clearance of apoptotic bodies leads to an accumulation of autoantigens (DNA, histones, RNPs). B cells lose tolerance and produce IgG autoantibodies against these antigens (e.g., anti-dsDNA, anti-Sm). These autoantibodies bind to their circulating targets to form immune complexes (Type III hypersensitivity). These complexes deposit in vascular beds (glomeruli, dermis, synovium, choroid plexus) where they activate the classical complement pathway. This consumes complement proteins (leading to low C3/C4) and triggers an influx of neutrophils and macrophages, causing intense localized tissue inflammation and damage. Additionally, autoantibodies can directly attack cells, such as red blood cells or platelets (Type II hypersensitivity), causing cytopenias.
Diagnostic Criteria & Guidelines
Diagnosed using the 2019 EULAR/ACR classification criteria. Requires an ANA titer >= 1:80 as an entry criterion. Then, weighted points are assigned across clinical domains (fever, skin, joints, neuro, serositis, renal) and immunologic domains (anti-dsDNA, anti-Sm, low C3/C4, positive antiphospholipid antibodies). A score of >= 10 confirms SLE.
All patients should be on an antimalarial agent, typically Hydroxychloroquine 200-400 mg PO daily, as it reduces flares, organ damage, and mortality. For mild flares (joints, skin): NSAIDs and short courses of low-dose corticosteroids (Prednisone 5-10 mg/day).
Second-Line & Adjunctive Therapy
For moderate-to-severe disease: Immunosuppressants such as Azathioprine, Methotrexate, or Mycophenolate mofetil. Biologics like Belimumab (BAFF inhibitor) or Anifrolumab (Type I IFN receptor antagonist) are used for refractory skin/joint disease. For severe Lupus Nephritis (Class III/IV): Induction therapy with High-dose IV Corticosteroids (Methylprednisolone 1g/day for 3 days) plus either IV Cyclophosphamide or PO Mycophenolate mofetil.
Surgical & Procedural Management
Renal transplantation for end-stage renal disease secondary to lupus nephritis. Joint replacements for avascular necrosis (a common complication of chronic high-dose steroid use).
Patient Counseling & Advice
Pregnancy must be planned during periods of disease quiescence (inactive for >6 months), as active lupus severely threatens both maternal and fetal survival. Anti-Ro/SSA antibodies can cross the placenta and cause neonatal lupus with congenital heart block. Stress the importance of never abruptly stopping corticosteroids.
Follow-Up & Monitoring Schedule
Routine monitoring every 3-6 months. Check blood pressure, urinalysis (for proteinuria/cellular casts), spot Urine Protein-to-Creatinine ratio, CBC, basic metabolic panel, Anti-dsDNA titers, and C3/C4 levels to predict flares.
Preventive Strategies
Sun protection is the primary preventive measure against cutaneous and systemic flares. Vaccination (pneumococcal, influenza) is critical as infection is a leading cause of death due to immunosuppression.
Survival has improved dramatically; 10-year survival is now >90%. However, patients face significant morbidity from chronic organ damage and medication side effects (especially steroids). Bimodal mortality: early death from active disease/infection, late death from accelerated cardiovascular disease.